Drug intelligence / Profile preview

RegenSkin

Development stage: Phase 1
Lead developer: Tianjin Ever Union Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

RegenSkin is an investigational cell therapy developed by Tianjin Ever Union Biotechnology for the treatment of moderate to severe plaque psoriasis. The therapy consists of umbilical cord-derived mesenchymal stem cells (UC-MSCs), which utilize a regenerative medicine approach to leverage the immunomodulatory and tissue regenerative properties of stem cells. Unlike conventional biologics that target specific inflammatory cytokines such as IL-17 or TNF-alpha, RegenSkin is designed to restore immune homeostasis by modulating systemic and local inflammatory environments. It is currently being evaluated in Phase 1 clinical trials to assess its safety and efficacy compared to the standard systemic treatment methotrexate in patients with moderate to severe chronic plaque psoriasis.

Brand names: RegenSkin
Other names: Umbilical cord-derived mesenchymal stem cellsUC-MSCs

Beyond the preview

Go deeper on RegenSkin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RegenSkin.

Explore the full profile